A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)

A Single-Dose, Open-Label, Three-Period Crossover Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets (FACT) Compared to Famotidine/Antacid EZ Chew Tablet Without Water and Famotidine/Antacid EZ Chew Tablet With Water

A study in 24 healthy subjects to assess the bioequivalence of Famotidine/Antacid EZ Chew tablet taken without water and with water compared to the Famotidine/Antacid tablet taken with water. Subjects will be given a single dose of each treatment separated by 5 to 7 days.

Inclusion Criteria:

• Female subject is not pregnant or lactating, Females of childbearing potential must use reliable means of contraception during the course of the study
• Subject is in good health
• Subject is able to abstain from smoking during the 24-hour periods before and during each treatment day

Exclusion Criteria:

• Subject has a history of stomach ulcers, other Gastrointestinal (GI) diseases or GI surgery
• Subject has a history of asthma or severe allergies to drugs or foods
• Subject currently uses prescribed or nonprescribed drugs on a regular basis
• Subject has a recent history of drug/alcohol abuse
• Subject consumes more than 6 cups of coffee per day
• Subject has unconventional or extreme dietary habits
• Subject has donated blood or has been in a clinical trial in which they received an investigational drug during the past 30 days
• Subject has a history of allergy or intolerance to antacids
• Female subject is known to be pregnant or is not using reliable means of contraception